TD Cowen initiated coverage of Ceribell (CBLL) with a Buy rating and $31 price target The company’s technology tackles the limitations of conventional EEG in the acute care setting, the analyst tells investors in a research note. The firm says this offers workflow benefits to physicians and staff and economic benefits to hospitals.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter